{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:30:06Z","timestamp":1787862606483,"version":"build-2784847793"},"reference-count":23,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2024,5,13]]},"DOI":"10.1248\/bpb.b24-00083","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T22:13:56Z","timestamp":1715552036000},"page":"946-954","source":"Crossref","is-referenced-by-count":2,"title":["Structure\u2013Activity Relationship Analysis of Fluoxetine for Suppression of Inflammatory Cytokine Production"],"prefix":"10.1248","volume":"47","author":[{"given":"Yohei","family":"Takenaka","sequence":"first","affiliation":[{"name":"Department of Radiation Biosciences, Graduate School of Pharmaceutical Sciences, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Applied Biological Science, Graduate School of Science and Technology, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kitabatake","sequence":"additional","affiliation":[{"name":"Department of Radiation Biosciences, Graduate School of Pharmaceutical Sciences, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Uchiumi","sequence":"additional","affiliation":[{"name":"Department of Gene Regulation, Graduate School of Pharmaceutical Sciences, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Bioorganic and Bioinorganic Chemistry, Graduate School of Pharmaceutical Sciences, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Kuramochi","sequence":"additional","affiliation":[{"name":"Department of Applied Biological Science, Graduate School of Science and Technology, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Tsukimoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Biosciences, Graduate School of Pharmaceutical Sciences, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Khanmohammadi S, Rezaei N. Role of Toll-like receptors in the pathogenesis of COVID-19. <i>J. Med. Virol.<\/i>, <b>93<\/b>, 2735\u20132739 (2021).","DOI":"10.1002\/jmv.26826"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rudd KE, Johnson SC, Agesa KM, <i>et al.<\/i> Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. <i>Lancet<\/i>, <b>395<\/b>, 200\u2013211 (2020).","DOI":"10.1016\/S0140-6736(19)32989-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. <i>Semin. Immunopathol.<\/i>, <b>39<\/b>, 517\u2013528 (2017).","DOI":"10.1007\/s00281-017-0639-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Rommasi F, Nasiri MJ, Mirsaeidi M. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features. <i>Mol. Cell. Biochem.<\/i>, <b>477<\/b>, 711\u2013726 (2022).","DOI":"10.1007\/s11010-021-04325-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gordon AC, Mouncey PR, Al-Beidh F, <i>et al.<\/i> Interleukin-6 receptor antagonists in critically Ill patients with covid-19. <i>N. Engl. J. Med.<\/i>, <b>384<\/b>, 1491\u20131502 (2021).","DOI":"10.1056\/NEJMoa2100433"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Luo Y, Kataoka Y, Ostinelli EG, Cipriani A, Furukawa TA. National prescription patterns of antidepressants in the treatment of adults with major depression in the U.S. between 1996 and 2015: a population representative survey based analysis. <i>Front. Psychiatry<\/i>, <b>11<\/b>, 35 (2020).","DOI":"10.3389\/fpsyt.2020.00035"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine <i>vs.<\/i> placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. <i>JAMA<\/i>, <b>324<\/b>, 2292\u20132300 (2020).","DOI":"10.1001\/jama.2020.22760"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) N\u00e9meth ZK, Sz\u0171cs A, Vitrai J, Juh\u00e1sz D, N\u00e9meth JP, Holl\u00f3 A. Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study. <i>Ideggyogy. Sz.<\/i>, <b>74<\/b>, 389\u2013396 (2021).","DOI":"10.18071\/isz.74.0389"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Reis G, Dos Santos Moreira-Silva EA, Silva DCM, <i>et al.<\/i> Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. <i>Lancet Glob. Health<\/i>, <b>10<\/b>, e42\u2013e51 (2022).","DOI":"10.1016\/S2214-109X(21)00448-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, Sirota M, Stevenson DK. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. <i>JAMA Netw. Open<\/i>, <b>4<\/b>, e2133090 (2021).","DOI":"10.1001\/jamanetworkopen.2021.33090"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Takenaka Y, Tanaka R, Kitabatake K, Kuramochi K, Aoki S, Tsukimoto M. Profiling differential effects of 5 selective serotonin reuptake inhibitors on TLRs-dependent and -independent IL-6 production in immune cells identifies fluoxetine as preferred anti-inflammatory drug candidate. <i>Front. Pharmacol.<\/i>, <b>13<\/b>, 874375 (2022).","DOI":"10.3389\/fphar.2022.874375"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Silvestri R, Artico M, La Regina G, Di Pasquali A, De Martino G, D\u2019Auria FD, Nencioni L, Palamara AT. Imidazole analogues of fluoxetine, a novel class of anti-Candida agents. <i>J. Med. Chem.<\/i>, <b>47<\/b>, 3924\u20133926 (2004).","DOI":"10.1021\/jm049856v"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Got\u014d H, \u014csawa E. Corner flapping: a simple and fast algorithm for exhaustive generation of ring conformations. <i>J. Am. Chem. Soc.<\/i>, <b>111<\/b>, 8950\u20138951 (1989).","DOI":"10.1021\/ja00206a046"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Got\u014d H, \u014csawa E. Further developments in the algorithm for generating cyclic conformers. Test with cycloheptadecane. <i>Tetrahedron Lett.<\/i>, <b>33<\/b>, 1343\u20131346 (1992).","DOI":"10.1016\/S0040-4039(00)91618-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Got\u014d H, \u014csawa E. An efficient algorithm for searching low-energy conformers of cyclic and acyclic molecules. <i>J. Chem. Soc., Perkin Trans. 2<\/i>, <b>2<\/b>, 187\u2013198 (1993).","DOI":"10.1039\/P29930000187"},{"key":"16","unstructured":"16) Frisch MJ, Trucks GW, Schlegel HB, <i>et al.<\/i> Gaussian 09, Revision D.01. Gaussian, Inc., Wallingford, CT. (2009)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hiemke C, H\u00e4rtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. <i>Pharmacol. Ther.<\/i>, <b>85<\/b>, 11\u201328 (2000).","DOI":"10.1016\/S0163-7258(99)00048-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Deodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. Assessing the mechanism of fluoxetine-mediated CYP2D6 inhibition. <i>Pharmaceutics<\/i>, <b>13<\/b>, 148 (2021).","DOI":"10.3390\/pharmaceutics13020148"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Choi BH, Choi JS, Yoon SH, Rhie DJ, Min DS, Jo YH, Kim MS, Hahn SJ. Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. <i>Neuropharmacology<\/i>, <b>41<\/b>, 443\u2013453 (2001).","DOI":"10.1016\/S0028-3908(01)00088-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Traboulsie A, Chemin J, Kupfer E, Nargeot J, Lory P. T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. <i>Mol. Pharmacol.<\/i>, <b>69<\/b>, 1963\u20131968 (2006).","DOI":"10.1124\/mol.105.020842"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Dhami KS, Churchward MA, Baker GB, Todd KG. Fluoxetine and its metabolite norfluoxetine induce microglial apoptosis. <i>J. Neurochem.<\/i>, <b>148<\/b>, 761\u2013778 (2019).","DOI":"10.1111\/jnc.14661"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Park J-Y, Kim S-W, Lee J-K, Im WB, Jin BK, Yoon SH. Simplified heterocyclic analogues of fluoxetine inhibit inducible nitric oxide production in lipopolysaccharide-induced BV2 cells. <i>Biol. Pharm. Bull.<\/i>, <b>34<\/b>, 538\u2013544 (2011).","DOI":"10.1248\/bpb.34.538"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bauer L, Manganaro R, Zonsics B, Strating JRPM, Kazzi PE, Lopez ML, Ulferts R, Hoey C, Mat\u00e9 MJ, Langer T, Coutard B, Brancale A, Kuppeveld FJM. Fluoxetine inhibits enterovirus replication by targeting the viral 2C protein in a stereospecific manner. <i>ACS Infect. Dis.<\/i>, <b>5<\/b>, 1609\u20131623 (2019).","DOI":"10.1021\/acsinfecdis.9b00179"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/5\/47_b24-00083\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T03:32:39Z","timestamp":1734751959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/5\/47_b24-00083\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00083","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"article-number":"b24-00083"}}